Evaluation of 8‐week glecaprevir/pibrentasvir treatment in direct‐acting antiviral‐naïve noncirrhotic HCV genotype 1 and 2infected patients in a real‐world setting in Japan

Based on high efficacy and safety demonstrated in clinical trials, treatment with glecaprevir/pibrentasvir (G/P) for 8 weeks is recommended for hepatitis C virus (HCV)–infected patients who are direct‐acting antiviral (DAA) naïve, genotype 1 or 2, and noncirrhotic. The aim of this study was to validate real‐world experience with 8‐week G/P treatment in Japan. We conducted a prospective observational cohort study in 554 patients who underwent...